Pramlintide Acetate Injection

Hyperphagia is a key driver in the development and progression of obesity. The product exerts precise appetite-suppressant effects by mimicking the physiological functions of endogenous amylin. Its core mechanism involves acting on amylin receptors (AMYRs) in the central nervous system, especially appetite-regulating centers such as the hypothalamus and nucleus tractus solitarius, to enhance satiety and reduce hunger. Concurrently, it delays gastric emptying, prolonging food retention in the gastrointestinal tract to further strengthen satiety, thereby reducing total caloric intake and achieving weight loss.

Clinical studies confirm that the product monotherapy produces significant weight loss. In chronic administration trials, intraperitoneal injection of pramlintide in male rats reduced caloric intake primarily by decreasing meal size, accompanied by slowed weight gain, with no significant effect on meal frequency, validating its core weight-loss mechanism via appetite suppression.

Notably, its combination with GLP-1 receptor agonists elicits synergistic weight-loss effects, exemplified by the CagriSema regimen (co-administration of the long-acting amylin analogue cagrilintide and semaglutide). As a first-generation amylin analogue, pramlintide shares an identical mechanism of action with cagrilintide and enhances appetite suppression through complementary pathways when combined with GLP-1 receptor agonists.

A central goal of obesity treatment is not only to reduce fat accumulation but also to prevent muscle loss during weight reduction. Decreased muscle mass lowers basal metabolic rate, impairing long-term maintenance of weight loss, increasing risks of complications such as fatigue and osteoporosis, and reducing treatment safety. Unlike some weight-loss agents (e.g., certain GLP-1 receptor agonists) and bariatric surgery, which often induce muscle loss, the product exhibits distinctive muscle-preserving potential during weight reduction, representing a key advantage over alternative weight-loss regimens.

Its muscle-protective mechanism is linked to amylin's physiological functions. As an amylin analogue, pramlintide modulates metabolic homeostasis, inhibiting fat synthesis and promoting lipolysis while reducing muscle protein degradation to maintain muscle mass. Preclinical studies and preliminary clinical observations indicate that amylin analogs preferentially reduce adipose tissue with minimal impact on muscle tissue, resulting in significantly lower muscle loss compared with GLP-1 receptor agonists.

This makes it particularly suitable for obese patients requiring long-term weight management, enabling weight reduction while preserving muscle function, maintaining basal metabolism, and preventing weight rebound.

For obese patients with comorbid diabetes, the muscle-preserving effect of pramlintide acetate injection holds greater clinical value. Such patients often experience reduced muscle mass due to insulin resistance and metabolic disorders.

Pramlintide aids glycemic control while preserving muscle to improve insulin sensitivity, creating a virtuous cycle of "weight loss–muscle preservation–glycemic control" and further reducing the risk of diabetic complications. Additionally, its acetate-modified structure improves drug tolerability, minimizing adverse reactions such as hypoglycemia and gastrointestinal discomfort, avoiding treatment discontinuation, and indirectly sustaining muscle-protective effects.

Pramlintide acetate injection has specific contraindicated populations. These populations are strictly prohibited from using this product to avoid serious safety risks. The contraindicated populations include: individuals who are allergic to pramlintide or any component of this product; patients with severe gastrointestinal diseases (such as severe gastric ulcer, duodenal ulcer, refractory nausea and vomiting); individuals with a history of hypoglycemic episodes that have not been effectively controlled; patients with severe renal insufficiency or undergoing dialysis treatment; pregnant and lactating women.

People who should use with caution should use under the guidance of a doctor, closely monitor the drug response, and adjust the dosage if necessary. People who should use with caution include: patients with moderate renal insufficiency, who do not need to adjust the dosage but need regular monitoring of renal function and blood glucose; patients with hepatic insufficiency, who mainly metabolize the drug through the kidneys, and the impact of hepatic insufficiency on its pharmacokinetics is relatively small, but still need close observation of adverse reactions.

Elderly people, who have a reduced metabolic capacity and a higher risk of hypoglycemia, need to start with a small dosage, slowly titrate, and strengthen blood glucose monitoring; children and adolescents, whose safety and efficacy of this drug have not been clearly established, and are not recommended for use.
In addition, patients with a history of epilepsy or a family history of epilepsy should exercise extreme caution when using this product, as a small number of studies have indicated that it may induce seizures. If symptoms of epilepsy occur, the product should be discontinued immediately and medical attention sought.